Attached files
| file | filename |
|---|---|
| EX-32 - EX-32 - Gene Biotherapeutics, Inc. | crxm-ex32_6.htm |
| EX-31.2 - EX-31.2 - Gene Biotherapeutics, Inc. | crxm-ex312_7.htm |
| EX-31.1 - EX-31.1 - Gene Biotherapeutics, Inc. | crxm-ex311_8.htm |
| EX-21.1 - EX-21.1 - Gene Biotherapeutics, Inc. | crxm-ex211_10.htm |
| EX-10.22 - EX-10.22 - Gene Biotherapeutics, Inc. | crxm-ex1022_312.htm |
| 10-K - 10-K - Gene Biotherapeutics, Inc. | crxm-10k_20151231.htm |
Exhibit 23.1
INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM’S CONSENT
We consent to the incorporation by reference in the Registration Statements of Taxus Cardium Pharmaceuticals Group, Inc. on Form S-8 (File Numbers 333-138666 and 333-142823) of our report, which includes an explanatory paragraph as to the Company’s ability to continue as a going concern, dated December 29, 2016, with respect to our audits of the consolidated financial statements of Taxus Cardium Pharmaceuticals Group, Inc. and Subsidiaries (the “Company”) as of December 31, 2015 and 2014 and for the years ended December 31, 2015 and 2014, which reports are included in this Annual Report on Form 10-K of Taxus Cardium Pharmaceuticals Group, Inc. for the year ended December 31, 2015.
/s/ Marcum LLP
Marcum LLP
New York, New York
December 29, 2016